NLM Gateway
A service of the U.S. National Institutes of Health
Your Entrance to
Resources from the
National Library of Medicine
    Home      Term Finder      Limits/Settings      Search Details      History      My Locker        About      Help      FAQ    
Skip Navigation Side Barintended for web crawlers only

(no title).

no author ; Conference on Retroviruses and Opportunistic Infections.

Program Abstr 6th Conf Retrovir Oppor Infect Conf Retrovir Oppor Infect 6th 1999 Chic Ill. 1999 Jan 31-Feb 4; 6th: 218 (abstract no. S36).

(no author)

It is likely that HIV viral resistance testing will be widely used within the next year. Although ideally large prospective studies of potential benefit should be performed, there will be many difficulties in obtaining meaningful results as both patients and clinicians are unlikely to remain uncertain about the potential benefits of these tests. Both retrospective analyses and small prospective studies indicate that a resistance test result is superior to the best guess of a clinician but the superiority over a response in viral load to a change of therapy is less certain. Resistance testing should be introduced in conjunction with validated measures of compliance and the ability to measure plasma levels of proteinase inhibitors. There is also a need to standardise presently available tests and to produce break points for phenotypic testing which are clinically validated. The development of phenotypic testing against combinations of drugs will extend their utility. The importance of rapid turn round for resistance testing is unclear as the speed of development of resistance with returning viraemia is unknown. Resistance testing will be used in the assessment of optimum therapy for post exposure prophylaxis and the treatment of pregnant women. The importance of resistance testing before starting initial therapy requires further surveys of the likelihood that resistant mutants are being transmitted and their detection in the absence of drug pressure. At present the greatest utility for resistance testing is likely to be in patients who have failed either one or several previous therapeutic regimes.

Publication Types:
  • Meeting Abstracts
Keywords:
  • Drug Therapy, Combination
  • Female
  • Humans
  • Pregnancy
  • Prospective Studies
  • Research Design
  • Viral Load
  • drug therapy
  • therapy
Other ID:
  • 20712010
UI: 102195540

From Meeting Abstracts




Contact Us
U.S. National Library of Medicine |  National Institutes of Health |  Health & Human Services
Privacy |  Copyright |  Accessibility |  Freedom of Information Act |  USA.gov